The InnovaBurn placental extracellular matrix medical device adheres and conforms to the wound site. Credit: Convatec / PRNewswire.

The US Food and Drug Administration (FDA) has approved the InnovaBurn placental extracellular matrix (ECM) medical device from Convatec.

This device is intended to manage complex surgical wounds and burns, including partial-thickness second-degree burns.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Part of the InnovaMatrix platform, InnovaBurn is a xenograft controlled for genetic variability as well as environmental and lifestyle factors, such as diet and activity levels.

The new device can be used to manage traumatic lacerations, dehisced incisional wounds, pressure and venous ulcers, post-surgical incisions, post-Mohs surgical wounds, and diabetic ulcers.

According to the company, InnovaBurn does not need preparation, specific placement orientation, tissue tracking or special storage.

Furthermore, the device is said to adhere and conform to wound sites.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

InnovaMatrix claims to be the first and only placental-derived medical device developed to manage burns as well as complex surgical and hard-to-heal wounds.

Produced using Convatec’s TriCleanse process, InnovaMatrix products, including the new InnovaBurn ECM, provide physicians with reproducible devices that sustain the inherent benefits of the placenta.

Convatec US Burn Division sales director Debra Noble said: “InnovaBurn is an innovative advancement in ECM technology for patients with partial-thickness, second-degree burns.

“InnovaBurn allows burn patients the benefits of the latest and best placental ECM technology. Our unique source material helps us to manufacture some of the largest ECM sizes in the industry much more affordably, so more patients have access to this brand new technology.

“Physicians tell us they appreciate the special sizing and InnovaBurn’s ease of use that help them manage larger wounds like burns.”